RECORD // Company

Crescent Biopharma, Inc.

Formerly: GLYCOMIMETICS INC

Built 2026-11-22T00:33:04Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Records under a former name (3)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Crescent Biopharma, Inc. · Ct business · same registered legal name as 'CRESCENT BIOPHARMA, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Crescent Biopharma, Inc. · Ctgov · same registered legal name as 'CRESCENT BIOPHARMA, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001628280-26-073389

ItemValuePeriodFormFiledAccessionReport
Revenue$3,117,0003 months ended 2026-09-3010-Q2026-11-120001628280-26-0733892026-11-22 00:33 UTCReport an error
Net income (loss)$-37,726,0003 months ended 2026-09-3010-Q2026-11-120001628280-26-0733892026-11-22 00:33 UTCReport an error
Interest expense$03 months ended 2026-09-3010-Q2026-11-120001628280-26-0733892026-11-22 00:33 UTCReport an error
Cash and cash equivalents$289,357,000at 2026-09-3010-Q2026-11-120001628280-26-0733892026-11-22 00:33 UTCReport an error
Contract liabilities, current$0at 2026-09-3010-Q2026-11-120001628280-26-0733892026-11-22 00:33 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001253689
Ticker
CBIO
CUSIP
G2545C104
Record ID
sx:sec:0001253689

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

32 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
State of incorporationE92026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Business address300 FIFTH AVENUE, WALTHAM, MA, 024512026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$10,844,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:33 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-153,942,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:33 UTCReport an error
Total assets (at 2025-12-31)$240,293,0002025-12-3110-K, XBRL Assets2026-11-22 00:33 UTCReport an error
Stockholders' equity (at 2025-12-31)$203,012,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:33 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$213,192,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:33 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-71,532,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:33 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$919,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:33 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,644,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:33 UTCReport an error
Form D total offering amount (D/A filed 2010-10-27)$50,000,0002010-10-27D/A2026-11-22 00:33 UTCReport an error
Form D total amount sold (D/A filed 2010-10-27)$38,979,4122010-10-27D/A2026-11-22 00:33 UTCReport an error
Form D industry groupPharmaceuticals2010-10-27D/A2026-11-22 00:33 UTCReport an error
Form D revenue rangeDecline to Disclose2010-10-27D/A2026-11-22 00:33 UTCReport an error
Form D date of first sale2009-10-202010-10-27D/A2026-11-22 00:33 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12)On November 12, 2026, Crescent Biopharma, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and Exhibits 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as…2026-11-12SEC EDGAR 8-K 0001628280-26-073409 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-15)On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1/2 ASCEND trial, (ii) the initiation of additional antibody-drug conjugates (“ADCs”) combination studies with CR-001, (iii) anticipated initiation of the Phase 1/2 APOLLO trial of CR-002, a topoisomerase inhibitor ADC targeting PD-L1, and (iv) the expected timing of clinical data readouts. Clinical Execution Progress in ASCEND, a Global Phase 1/2 Trial of CR-001 In the global Phase 1/2 ASCEND of…2026-10-15SEC EDGAR 8-K 0001628280-26-066006 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-07-30)On July 30, 2026, Crescent Biopharma, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and Exhibits 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or…2026-07-30SEC EDGAR 8-K 0001628280-26-050805 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$74,403,2522026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #2 (13F as filed): BVF INC/IL$49,477,7342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #3 (13F as filed): Fairmount Funds Management LLC$49,461,5882026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #4 (13F as filed): Venrock Adviser, LLC$38,404,3682026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #5 (13F as filed): Logos Global Management LP$34,200,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #6 (13F as filed): FCPM III SERVICES B.V.$30,201,3362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #7 (13F as filed): Balyasny Asset Management L.P.$29,932,5062026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #8 (13F as filed): Vestal Point Capital, LP$29,340,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #9 (13F as filed): Opaleye Management Inc.$23,748,3182026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #10 (13F as filed): BlackRock, Inc.$22,891,7162026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.